Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Dexmedetomidine

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 1 (1)

Trial Status

Active Not Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06639659Not ApplicableActive Not RecruitingPrimary

Sphenopalatine Block vs Dexmedetomidine Infusion in Trans Nasal Endoscopic Pituitary Surgery

NCT05707754Phase 1CompletedPrimary

Sphenopalatine Ganglion Block Study

Showing all 2 trials

Research Network

Common Treatments

  • Dexmedetomidine1
  • General Anesthesia Control Group1
  • Angiocatheter1
  • Sphenopalatine Ganglion Block1
  • Bupivacaine1

Active Sponsors

  • Zagazig University1
  • Montefiore Medical Center1

Top Investigators

Related Conditions

  • Transnasal Endoscopic Pitutary Surgery1

Activity Timeline